Zobrazeno 1 - 10
of 20
pro vyhledávání: '"H, Flight"'
Autor:
N. P. Scott, D. D. Remoundos, Pankaj G. Roy, Fergus V. Gleeson, H Flight, Cheng Liu, Simon Lord, Daniel R. McGowan, L. Mustata, J. Niederer, G. M. MacLean, Cameron Snell, A L Harris, B. E. Jones, Eugene Teoh
Publikováno v:
British Journal of Cancer. 126:598-605
Background 18F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of 18F-fluciclovin
Autor:
Maddison Dix, Carlene J. Wilson, Ingrid H. Flight, Molla M. Wassie, Graeme P. Young, Charles Cock, Sarah Cohen‐Woods, Erin L. Symonds
Publikováno v:
European journal of cancer careREFERENCES. 31(6)
This is to determine whether health beliefs regarding colorectal cancer (CRC) screening could predict discomfort with a change to CRC surveillance proposing regular faecal immunochemical tests (FIT) instead of colonoscopy.Eight hundred individuals en
Autor:
Clare E. McGuiness, Deborah Turnbull MPsych(Clin), PhD, Carlene Wilson PhD, MBA, Amy Duncan PhD, Ingrid H. Flight MPH, PhD, Ian Zajac PhD
Publikováno v:
American Journal of Men's Health, Vol 11 (2017)
Men’s participation in cancer screening may be influenced by their thinking style. Men’s need for cognition (NFC) and faith in intuition were measured to explore whether they varied by demographic variables or predicted screening behavior. Austra
Externí odkaz:
https://doaj.org/article/68ca8645f2cb4e498deda27a5bd83520
Autor:
N P, Scott, E J, Teoh, H, Flight, B E, Jones, J, Niederer, L, Mustata, G M, MacLean, P G, Roy, D D, Remoundos, C, Snell, C, Liu, F V, Gleeson, A L, Harris, S R, Lord, D R, McGowan
Publikováno v:
British journal of cancer. 126(4)
Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration ofA reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer.
Autor:
C Qi, Dionisios Stavroulias, J L Derham, Michael Skwarski, E Belcher, Joshua A. Bull, P Ferencz, Chu K-Y., Fergus V. Gleeson, Daniel P. Bulte, Paula L. Croal, Francesca M. Buffa, Adrian L. Harris, O’Connor Jpb., Marcus Green, Harris Bhl., H Flight, Leticia Campo, D O’Reilly, J Chauhan, Jane Holmes, Mark McCole, Geoff S. Higgins, Gonzalo Rodriguez-Berriguete, F Di Chiara, W G McKenna, Eugene Teoh, Lisa K. Folkes, Ruth MacPherson, Daniel R. McGowan, Philip S. Macklin, Remko Prevo
Publikováno v:
Clin Cancer Res
Purpose: Tumor hypoxia fuels an aggressive tumor phenotype and confers resistance to anticancer treatments. We conducted a clinical trial to determine whether the antimalarial drug atovaquone, a known mitochondrial inhibitor, reduces hypoxia in non
Autor:
Ingrid H, Flight, Janine, Chapman, Nathan J, Harrison, Jeff, Bull, Christine, Christensen, Bogda, Koczwara, Carlene J, Wilson
Publikováno v:
Journal of cancer education : the official journal of the American Association for Cancer Education. 37(3)
This study reports preliminary data about the information needs of esophago-gastric cancer survivors and their supporters across diagnosis and treatment by identifying time-specific needs and whether the information provided aligned with the needs at
Autor:
Michael Skwarski, Marcus Green, P Ferencz, Dionisios Stavroulias, H Flight, J Chauhan, Francesca M. Buffa, Daniel R. McGowan, Gonzalo Rodriguez-Berriguete, E Belcher, F Di Chiara, Remko Prevo, Daniel P. Bulte, Geoff S. Higgins, C Qi, Philip S. Macklin, Ruth MacPherson, Mark McCole, D O’Reilly, Jane Holmes
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:S173
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
H. Flight, Linda Davies, Harpreet Wasan, A Lamarca, Juan W. Valle, John Bridgewater, Daniel H. Palmer, R Hubner, W. D. Ryder, Jane Rogan
Publikováno v:
Annals of Oncology. 25:iv252
Background: Since the randomized NCRN phase III ABC-02 trial, there exists level A evidence for first-line chemotherapy with cisplatin and gembitabine combination in ABC. To date, no robust evidence is available supporting the use of second-line trea
Autor:
H. Flight, Corinne Faivre-Finn
Publikováno v:
Lung Cancer. 60:S3-S4